NANT Homepage
NANT Homepage About Us How You Can Help NANT Trials Contact Us Search the Site

Menu

Publications

Publications from studies of the NANT consortium as well as from research of investigators in the NCI Program Project "Biology and Therapy of High-Risk Neuroblastoma" are available for download from this site.

Please select from the drop-down menu below to view the list of available downloads for that year. Downloadable articles are linked in green. Please click or right-click and choose "Save As" to download them. Articles which are not yet available are not linked.

Publications are arranged in chronological order and alphabetically by last name.

Publications from 2000

  1.   Anderson, C. P., Keshelava, N., Satake, N., Meek, W. H., and Reynolds, C. P.
    Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression. Med.Pediatr.Oncol., 35: 659-662, 2000.
  2.   Keshelava, N., Zuo, J. J., Waidyaratne, N. S., Triche, T. J., and Reynolds, C. P.
    p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med.Pediatr.Oncol., 35: 563-568, 2000.
  3.   Keshelava, N., Groshen, S., and Reynolds, C. P.
    Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother.Pharmacol., 45: 1-8, 2000.
  4.   Matthay, K. K. and Reynolds, C. P.
    Is there a role for retinoids to treat minimal residual disease in neuroblastoma? Br.J.Cancer, 83:1121-1123, 2000.
  5.   Maurer, B. J., Melton, L., Billups, C., Cabot, M. C., and Reynolds, C. P.
    Synergistic cytotoxicity in solid tumor cell lines between N-(4- hydroxyphenyl)retinamide and modulators of ceramide metabolism. J.Natl.Cancer Inst., 92: 1897-1909, 2000.
  6.   Reynolds, C. P. and Seeger, R. C.
    Neuroblastoma. In C. M. Haskell (ed.), Cancer Treatment, Fifth ed, pp. 1214-1236. Philadelphia: W.B. Saunders, 2000.
  7.   Seeger, R. C., Reynolds, C. P., Gallego, R., Stram, D. O., Gerbing, R. B., and Matthay, K. K.
    Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J.Clin.Oncol, 18: 4067-4076, 2000.

Publications from 2001

  1.   Anderson, C. P., Seeger, R. C., Satake, N., Monforte-Munoz, H. L., Keshelava, N., Bailey, H.H., and Reynolds, C. P.
    Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J.Pediatr.Hematol.Oncol., 23: 500-505, 2001.
  2.   Keshelava, N., Zuo, J. J., Chen, P., Waidyaratne, S. N., Luna, M. C., Gomer, C. J., Triche, T. J., and Reynolds, C. P.
    Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res, 61:6185-6193, 2001.
  3.   Metelitsa, L. S., Naidenko, O. V., Kant, A., Wu, H. W., Loza, M. J., Perussia, B., Kronenberg, M., and Seeger, R. C.
    Human NKT Cells Mediate Antitumor Cytotoxicity Directly by Recognizing Target Cell CD1d with Bound Ligand or Indirectly by Producing IL-2 to Activate NK Cells. J.Immunol., 167: 3114-3122, 2001.
  4. Reynolds, C. P. and Lemmons, R. S.
    Retinoid therapy of childhood cancer. Hematol.Oncol Clin.North Am., 15: 867-910, 2001.
  5.   Reynolds, C. P. and Seeger, R. C.
    Detection of Minimal Residual Disease in Bone Marrow During or After Therapy as a Prognostic Marker for High-Risk Neuroblastoma. Am.J.Pediatr.Hematol.Oncol., 23: 150-152, 2001.
  6.   Tang, H. R., Da Silva, A. J., Matthay, K. K., Price, D. C., Huberty, J. P., Hawkins, R. A., and Hasegawa, B. H.
    Neuroblastoma imaging using a combined CT scanner-scintillation camera and 131I-MIBG. J.Nucl.Med., 42: 237-247, 2001.
  7.   Wang, H., Maurer, B. J., Reynolds, C. P., and Cabot, M. C.
    N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res, 61: 5102-5105, 2001.

Publications from 2002

  1.   Anderson, C. P. and Reynolds, C. P.
    Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant., 30:135-140, 2002.
  2.   Erdreich-Epstein, A., Tran, L.B., Bowman, N. N., Wang, H., Cabot, M.C., Durden, D.L., Vlckova, J., Reynolds, C. P., Stins, M.F., Groshen, S., Millard, M.
    Ceramide Signaling in Fenretinide-induced Endothelial Cell Apoptosis. The Journal of Biological Chemistry, 277:49531-49537, 2002.
  3.   Ho R. Eggert A. Hishiki T. Minturn JE. Ikegaki N. Foster P. Camoratto AM. Evans AE. Brodeur GM.
    Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Research. 62:6462-6, 2002
  4.   Houghton, P.J., Adamson, P.C., Blaney, S., Fine, H.A., Gorlick, R., Haber, M., Helman, L., Hirschfeld, S., Hollingshead, M.G., Israel, M.A., Lock, R.B., Maris, J.M., Merlino, G., Patterson, W., Reynolds, C.P., Shannon, K., Yu, A., Yu, J., Smith, M.A.
    Testing of New Agents in Childhood Cancer Preclinical Models: Meeting Summary, Clinical Cancer Research, 8:3646-3657, 2002.
  5. Wigginton J.M., Wiltrout R.H.
    IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Expert Opinion on Biological Therapy. 2:513-24, 2002.
  6.   Yanik, G. A., Levine, J. E., Matthay, K. K., Sisson, J. C., Shulkin, B. L., Shapiro, B., Hubers, D., Spalding, S., Braun, T., Ferrara, J. L., and Hutchinson, R. J.
    Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J.Clin.Oncol, 20: 2142-2149, 2002.

Publications from 2003

  1.   Haas-Kogan, D.A., Swift, P.S., Selch, M., Haase, G.M., Seeger, R.C., Gerbing, R.B., Stram, D.O., Matthay, K.K.
    Impact of Radiotherapy for High-Risk Neuroblastoma: A Children's Cancer Group Study. Int. J. Radiation Oncology Biol. Phys., 56: 28-39, 2003
  2.   Jaboin J. Hong A. Kim CJ. Thiele CJ.
    Cisplatin-induced cytotoxicity is blocked by brain-derived neurotrophic factor activation of TrkB signal transduction path in neuroblastoma. Cancer Letters. 193:109-14, 2003.
  3.   Keshelava, N., Tsao-Wei, D., Reynolds, C. P.
    Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p53. Clinical Cancer Research, 9:3492-3502, 2003.
  4.   Matthay, K.K., Edeline, V., Lumbroso, J., Tanguy, M.L., Asselain, B. Zucker, J.M., Valteau-Couanet, D., Hartmann, O., Michon, J.
    Correlation of Early Metastatic Response by 123I-Metaiodobenzylguanidine Scintigraphy With Overall Response and Event-Free Survival in Stage IV Neuroblastoma. Journal of Clinical Oncology, 21: 2486-2491, 2003.
  5.   Reynolds, C. P., Matthay, K. K., Villablanca, J. G., Maurer, B. J.
    Retinoid Therapy of High-Risk Neuroblastoma. Cancer Letters, 197:185-192, 2003.
  6.   Sohara, Y., Shimada, H., Scadeng, M., Pollack, H., Yamada, S., Ye, W., Reynolds, C. P., and DeClerck, Y. A.
    Lytic Bone Lesions in Human Neuroblastoma Xenograft Involve Osteoclast Recruitment and Are Inhibited by Bisphosphonate. Cancer Research 63:3026-3031, 2003.
  7.   Weiss, B., Vora, A., Matthay, K.K., Huberty, J., Hawkins, R.A.
    Secondary Myelodysplastic Syndrome and Leukemia Following 131I-Metaiodobenzylguanidine Therapy for Relapsed Neuroblastoma. Journal of Pediatric Hematology/Oncology, 25: 2003.
  8.   Yang, B., Keshelava, N., Anderson, C.P. and Reynolds, C.P.
    Antagonism of Buthionine Sulfoximine Cytotoxicity for Human Neuroblastoma Cell Lines by Hypoxia Is Reversed by the Bioreductive Agent Tirapazamine. Cancer Research 63:1520-1526, 2003

Publications from 2004

  1.   Adkins, E. S., Sawin, R., Gerbing, R. B., London, W. B., Matthay, K. K., and Haase, G. M.
    Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. J.Pediatr.Surg., 39: 931-936, 2004.
  2.   Batra, S., Reynolds, C. P., and Maurer, B. J.
    Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res., 64: 5415-5424, 2004.
  3.   DuBois, S. G., Messina, J., Maris, J. M., Huberty, J., Glidden, D. V., Veatch, J., Charron, M., Hawkins, R., and Matthay, K. K.
    Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J.Clin.Oncol., 22: 2452-2460, 2004.
  4. Goldsby, R. E. and Matthay, K. K.
    Neuroblastoma : evolving therapies for a disease with many faces. Paediatr.Drugs, 6: 107-122, 2004.
  5.   Hickeson, M. P., Charron, M., Maris, J. M., Brophy, P., Kang, T. I., Zhuang, H., Khan, J., and Nevrotski, T.
    Biodistribution of post-therapeutic versus diagnostic (131)I-MIBG scans in children with neuroblastoma. Pediatr.Blood Cancer, 42: 268-274, 2004.
  6.   Reynolds, C. P., Maurer, B. J., and Kolesnick, R. N.
    Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett., 206: 169-180, 2004.
  7. Reynolds, C. P.
    Detection and treatment of minimal residual disease in high-risk neuroblastoma. Pediatr.Transplant., 8: 56-66, 2004.
  8.   Vratilova, J., Frgala, T., Maurer, B. J., and Reynolds, C.P.
    Liquid chromatography method for quantifying N-(4-hydroxyphenyl)retinamide and N-(4-methoxyphenyl)retinamide in tissues. J.Chromatogr.B Analyt.Technol.Biomed.Life Sci., 808: 125-130, 2004.
  9.   Wagner, L. M., Crews, K. R., Iacono, L. C., Houghton, P. J., Fuller, C. E., McCarville, M. B., Goldsby, R. E., Albritton, K., Stewart, C. F., and Santana, V. M.
    Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin.Cancer Res., 10: 840-848, 2004.

Publications from 2005

  1.   Grigoryan, R., Keshelava, N., Anderson, C., and Reynolds, C. P.
    In vitro testing of chemosensitivity in physiological hypoxia. Methods Mol.Med., 110: 87-100, 2005.
  2.   Howard, J. P., Maris, J. M., Kersun, L. S., Huberty, J. P., Cheng, S. C., Hawkins, R. A., and Matthay, K. K.
    Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma. Pediatr.Blood Cancer, 44: 232-239, 2005.
  3.   Qualman,S.J., Bowen,J., Fitzgibbons,P.L., Cohn,S.L. and Shimada,H.
    Protocol for the examination of specimens from patients with neuroblastoma and related neuroblastic tumors, Arch.Pathol.Lab Med., 129: 874-883, 2005.
  4.   Reynolds, C. P., Sun, B. C., DeClerck, Y. A., and Moats, R. A.
    Assessing growth and response to therapy in murine tumor models. Methods Mol.Med., 111: 335-350, 2005.
  5.   Reynolds, C. P. and Maurer, B. J.
    Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol.Med., 110: 173-183, 2005.
  6.   Shimada,H.
    In situ neuroblastoma: an important concept related to the natural history of neural crest tumors, Pediatr.Dev.Pathol., 8: 305-306, 2005.
  7.   Sohara,Y., Shimada,H. and DeClerck,Y.A.
    Mechanisms of bone invasion and metastasis in human neuroblastoma, Cancer Lett., 228: 203-209, 2005.
  8.   Sohara, Y., Shimada, H., Minkin, C., Erdreich-Epstein, A., Nolta, J. A., and DeClerck, Y. A.
    Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Res., 65: 1129-1135, 2005.
  9.   Wall,S.J., Werner,E., Werb,Z. and DeClerck,Y.A.
    Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen, J.Biol.Chem., 280: 40187-40194, 2005.

Publications from 2006

  1.   Judith G. Villablanca, Mark D. Krailo, Matthew M. Ames, Joel M. Reid, Gregory H. Reaman, and C. Patrick Reynolds
    Phase I Trial of Oral Fenretinide in Children With High-Risk Solid Tumors: A Report From the Children's Oncology Group (CCG 09709), J Clin Oncol 24:3423-3430, 2006.
  2.   Chantrain,C.F., Henriet,P., Jodele,S., Emonard,H., Feron,O., Courtoy,P.J., DeClerck,Y.A. and Marbaix,E.
    Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases, Eur.J.Cancer, 42: 310-318, 2006.
  3.   Grupp S.A., Cohn S.L., Wall D., Reynolds C.P.
    Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: saving for a rainy day, Pediatr. Blood Cancer, 46: 719-722, 2006.
  4.   Jodele,S., Blavier,L., Yoon,J.M. and DeClerck,Y.A.
    Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression, Cancer Metastasis Rev., 25: 35-43, 2006.
  5.   Matthay,K.K.
    Is liver metastasis in neuroblastoma an indication for treatment reduction?, Pediatr.Blood Cancer, 46: 269-270, 2006.
  6.   Matthay,K.K., Tan,J.C., Villablanca,J.G., Yanik,G.A., Veatch,J., Franc,B., Twomey,E., Horn,B., Reynolds,C.P., Groshen,S., Seeger,R.C. and Maris,J.M.
    Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study, J.Clin.Oncol., 24: 500-506, 2006.
  7.   Messina,J.A., Cheng,S.C., Franc,B.L., Charron,M., Shulkin,B., To,B., Maris,J.M., Yanik,G., Hawkins,R.A. and Matthay,K.K.
    Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma, Pediatr.Blood Cancer, 2006.
  8.   Mouchess,M.L., Sohara,Y., Nelson,M.D., Jr., DeClerck,Y.A. and Moats,R.A.
    Multimodal imaging analysis of tumor progression and bone resorption in a murine cancer model, J.Comput.Assist.Tomogr., 30: 525-534, 2006.
  9.   Osenga,K.L., Hank,J.A., Albertini,M.R., Gan,J., Sternberg,A.G., Eickhoff,J., Seeger,R.C., Matthay,K.K., Reynolds,C.P., Twist,C., Krailo,M., Adamson,P.C., Reisfeld,R.A., Gillies,S.D. and Sondel,P.M.
    A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group, Clin.Cancer Res., 12: 1750-1759, 2006.
  10.   Sano,H., Bonadio,J., Gerbing,R.B., London,W.B., Matthay,K.K., Lukens,J.N. and Shimada,H.
    International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age, Eur.J.Cancer, 42: 1113-1119, 2006.
  11.   Wu,X., Kim,Y., Sun,B.C., Moore,J.D., Shaw,W.A. and Maurer,B.J.
    Liquid chromatography method for quantifying D-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (D-threo-PPMP) in mouse plasma and liver, J.Chromatogr.B Analyt.Technol.Biomed.Life Sci., 837: 44-48, 2006.

Publications from 2007

  1.   Frgala T, Kalous O, Proffitt RT, Reynolds CP
    A novel cytotoxicity assay with a 4 log dynamic range that identifies synergistic drug combinations. Molecular Cancer Therapeutics 6:886-897, 2007.
  2. Harned TM, Kalous O, Neuwelt A, Loera J, Ji L, Iovine P, Sposto R, Neuwelt EA, Reynolds CP
    Sodium Thiosulfate (STS) administered six hours after cisplatin does not compromise anti-neuroblastoma activity. Clinical Cancer Research (In Press, 2007).
  3. Keshelava N, Davicioni E, Zesheng Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP
    Inhibition of histone deacetylase (HDAC) 1, a drug target identified by expression profiling, sensitizes multi-drug-resistant neuroblastoma cell lines to cytotoxic agents. J National Cancer Institute (In Press, 2007)
  4.   Keshelava N, Davicioni E, Zesheng Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP
    Inhibition of histone deacetylase (HDAC) 1, a drug target identified by expression profiling, sensitizes multi-drug-resistant neuroblastoma cell lines to cytotoxic agents. J National Cancer Institute 99:1107-19, 2007.
  5.   Maurer BJ, Kalous O, Yesair DW, Wu X, Vratilova J, Maldonado V, Khankaldyyan V, Frgala T, Sun BC, McKee RT, Burgess SW, Shaw WA, Reynolds CP
    Improved oral delivery of N-(4-hydroxyphenyl)retinamide with novel LYM-X-SORBTM organized lipid complex in mice. Clinical Cancer Research 13:3079-3086, 2007.
  6.   Peng H, Sohara Y, Moats RA, Nelson MD Jr, Groshen SG, Ye W, Reynolds CP, DeClerck YA
    The activity of zoledronic acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and ras-mediated tumor cell survival and proliferation. Cancer Research 67:9346-55, 2007.
  7. Song L, Ara T, Wu HW, Woo CW, Reynolds CP, Seeger RC, DeClerck YA, Thiele CJ, Richard Sposto R, Metelitsa LS
    MYCN oncogene negatively regulates localization of Va24-invariant natural killer T cells to the disease site in neuroblastoma. J Clinical Investigation (In Press, 2007)